|
Chinese pharmaceutical companies are stepping up their push into the US generic drugs market with the number of approvals for copycat medicines almost doubling last year. 中国制药公司正加大力度打入美国仿制药市场，去年中国药企获批的仿制药品种增加近一倍。 In 2017, Chinese drugmakers won US Food and Drug Administration approval for 38 generic drugs, cheaper versions of treatments for which patents have expired, up from 22 a year earlier. This month, Jiangsu Hengrui Medicine, China’s largest pharmaceutical company with a $35bn market capitalisation, became the latest to win approval for its generic of anaesthetic desflurane. 2017年，中国药企共有38款仿制药（专利已过期、其他药企可以仿制的较低价药品）获得了美国食品药品管理局(FDA)的批准，而上一年这个数字为22款。本月，市值350亿美元的中国最大药企江苏恒瑞医药(Jiangsu Hengrui Medicine)凭借其仿制麻醉剂地氟烷(desflurane)，成为最新一家获FDA认证的中国药企。 | 
